VINC vs. INDP, NERV, NRSN, VBIV, AYTU, TLPH, TRAW, ORGS, VAXX, and APM
Should you be buying Vincerx Pharma stock or one of its competitors? The main competitors of Vincerx Pharma include Indaptus Therapeutics (INDP), Minerva Neurosciences (NERV), NeuroSense Therapeutics (NRSN), VBI Vaccines (VBIV), Aytu BioPharma (AYTU), Talphera (TLPH), Traws Pharma (TRAW), Orgenesis (ORGS), Vaxxinity (VAXX), and Aptorum Group (APM). These companies are all part of the "pharmaceutical preparations" industry.
Vincerx Pharma (NASDAQ:VINC) and Indaptus Therapeutics (NASDAQ:INDP) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, community ranking, risk, valuation and dividends.
44.0% of Vincerx Pharma shares are held by institutional investors. Comparatively, 7.1% of Indaptus Therapeutics shares are held by institutional investors. 22.9% of Vincerx Pharma shares are held by company insiders. Comparatively, 27.1% of Indaptus Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
In the previous week, Indaptus Therapeutics had 5 more articles in the media than Vincerx Pharma. MarketBeat recorded 6 mentions for Indaptus Therapeutics and 1 mentions for Vincerx Pharma. Vincerx Pharma's average media sentiment score of 1.89 beat Indaptus Therapeutics' score of 1.19 indicating that Vincerx Pharma is being referred to more favorably in the media.
Vincerx Pharma has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500. Comparatively, Indaptus Therapeutics has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500.
Indaptus Therapeutics' return on equity of -108.14% beat Vincerx Pharma's return on equity.
Vincerx Pharma received 10 more outperform votes than Indaptus Therapeutics when rated by MarketBeat users. However, 83.33% of users gave Indaptus Therapeutics an outperform vote while only 64.52% of users gave Vincerx Pharma an outperform vote.
Vincerx Pharma presently has a consensus target price of $5.00, suggesting a potential upside of 557.89%. Indaptus Therapeutics has a consensus target price of $12.00, suggesting a potential upside of 466.04%. Given Vincerx Pharma's higher probable upside, equities research analysts plainly believe Vincerx Pharma is more favorable than Indaptus Therapeutics.
Indaptus Therapeutics is trading at a lower price-to-earnings ratio than Vincerx Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
Indaptus Therapeutics beats Vincerx Pharma on 7 of the 13 factors compared between the two stocks.
Get Vincerx Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for VINC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VINC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vincerx Pharma Competitors List
Related Companies and Tools
